News

Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights

--Cash runway extended late into calendar Q2 2023 --Tumor control achieved following MDNA11 treatment in 3 out of 8 patients…

2 years ago

ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares

TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or…

2 years ago

ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application

TORONTO, Ontario and CAMBRIDGE, Massachusetts , June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS”…

2 years ago

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

PITTSBURGH, June 22, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy,…

2 years ago

Tonix Pharmaceuticals Announces Pricing of $30 Million Private Placement of Convertible Redeemable Preferred Stock

CHATHAM, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced…

2 years ago

TScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium

WALTHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the…

2 years ago

BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022

RESEARCH TRIANGLE PARK, N.C., June 22, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations…

2 years ago

Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

ACT-AD ERP P300 Latency post hoc analysis: mITT population, Wilcoxon analysis ACT-AD ERP P300 Latency post hoc analysis: mITT population,…

2 years ago

Alladapt Announces Completion of Oversubscribed $119 Million Institutional Financing

Financing from new and existing investors will support continued development of a novel treatment for food allergy Jim Momtazee and…

2 years ago

Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

2 years ago